Polyrizon Ltd. (PLRZ)
| Market Cap | 20.91M +232.3% |
| Revenue (ttm) | n/a |
| Net Income | -4.58M |
| EPS | -3.13 |
| Shares Out | 2.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,245 |
| Open | 8.90 |
| Previous Close | 8.58 |
| Day's Range | 8.47 - 8.90 |
| 52-Week Range | 2.88 - 18.20 |
| Beta | -1.15 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 29, 2026 |
About PLRZ
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Financial Performance
Financial StatementsNews
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
All 120 planned participants randomized across five clinical sites in the United States Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”),...
Polyrizon files U.S. patent application for mucoadhesive technology
Polyrizon (PLRZ) announced that it has filed a new U.S. divisional patent application with the United States Patent and Trademark Office, or USPTO, further expanding the company’s intellectual propert...
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
A new patent application covers Polyrizon's proprietary mucoadhesive platform and its potential applications in nasal drug delivery.
Polyrizon enrolls first patient in U.S. study of NASARIX
Polyrizon (PLRZ) announced the enrollment of the first patient in its U.S. clinical study to evaluate NASARIX, the Company’s investigational Allergy Blocker, in patients with seasonal allergic rhiniti...
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
First patient marks Polyrizon's transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in...
Polyrizon files to sell 404,166 ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 404,166 ordinary shares. The company is not selling any shares under…
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd.
Polyrizon announces $4.0M registered direct offering
Polyrizon (PLRZ) announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered…
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
RAANANA, ISRAEL, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogel...
Polyrizon completes all five U.S. site contracts for Nasarix allergy study
Polyrizon (PLRZ) announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of Nasarix Allergy Blocker. With the execution of these final…
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
Raanana, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intr...
Polyrizon completes clinical site network for NASARIX study
Polyrizon (PLRZ) has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX Allergy Blocker. With the execution of these final agreements, Polyri...
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (N...
Polyrizon announces results from Nasarix biocompatibility evaluation program
Polyrizon (PLRZ) announced results from its biocompatibility evaluation program for its proprietary Nasarix Allergy Blocker nasal spray, with all required biological safety tests meeting their predete...
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intra...
Polyrizon receives central IRB approval for Nasarix
Polyrizon (PLRZ) announced it has received central IRB approval to begin its first human clinical trial for Nasarix, the company’s nasal spray designed to block airborne allergens. Published first on…
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intra...
Polyrizon gets patent for Trap & Target mucoadhesive polymer technology platform
Polyrizon (PLRZ) announced the publication of U.S. patent application No. US 2024/0358741 A1, titled “Mucoadhesive Polymers for Nasal Drug Delivery”. The patent application covers Polyrizon’s propriet...
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intra...
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker's protective barrier funct...
Polyrizon receives notice of European patent publication
Polyrizon (PLRZ) announced that the European Patent Office, or EPO, has completed the technical preparations for the publication of the company’s European patent application entitled “Mucoadhesive Pol...
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intra...
Polyrizon signs agreements with two additional clinical sites for Nasarix study
Polyrizon (PLRZ) announced it has signed agreements with two additional U.S. clinical sites. This brings the total to three major contracted sites for its upcoming Nasarix clinical study. These three…
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intra...
Polyrizon signs clinical trial agreement with clinical research site for Nasarix
Polyrizon (PLRZ) announced the signing of its first clinical trial agreement with a U.S.-based clinical research site specializing in allergy studies, marking a milestone toward the initiation of its ...